delandistrogene moxeparvovec

AXP000254.1 · Viral vector gene therapy

Platform
AAVrh74 vector
Targets
DMD
Originator
Nationwide Children's Hospital
Sponsor
Sarepta Therapeutics

Names

NameTypeSource
delandistrogene moxeparvovecpreferred namecurator
Elevidysbrandfda
SRP-9001codefda

Virus

Role
In vivo gene transfer
Family
Parvoviridae
Virus
adeno-associated virus rh74
Strain
AAVrh74
Replication
non replicating
Modifications
MHCK7 (myosin heavy chain kinase 7) promoter
Transgenes
micro-dystrophin (DMD)
Route
intravenous
Source
evidence

Approvals

AgencyRegionDateStatusBrandIndicationSource
FDAUS2023-06-22conditionalElevidysAccelerated approval: ambulatory paediatric patients aged 4 through 5 with a confirmed DMD mutation; extended to patients 4 and older by a 2024-06-20 supplementsource
PMDAJP2025-05-13conditionalElevidysDuchenne muscular dystrophy in ambulatory patients aged 3 to under 8 years who are negative for anti-AAVrh74 antibodies; conditional and time-limited approval, for three yearssource

Clinical trials (11)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07542314Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing SettingRecruitingPhase 42026-11-302027-08-3120Duchenne Muscular Dystrophy
NCT06597656A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74TerminatedPhase 12024-09-182025-08-053Duchenne Muscular Dystrophy
NCT06270719An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular DystrophyEnrolling by invitation2024-02-072028-12-31500Duchenne Muscular Dystrophy
NCT06241950A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)TerminatedPhase 12024-01-292025-10-105Duchenne Muscular Dystrophy
NCT06128564A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)Active not recruitingPhase 22023-11-292026-03-0413Duchenne Muscular Dystrophy
NCT05967351A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical StudyEnrolling by invitationPhase 32023-09-272033-10-31400Duchenne Muscular Dystrophy
NCT05881408A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)Active not recruitingPhase 32023-05-312027-05-31148Duchenne Muscular Dystrophy
NCT05096221A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)CompletedPhase 32021-10-272023-10-04126Duchenne Muscular Dystrophy
NCT04626674A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory CohortRecruitingPhase 12020-11-232027-12-3183Duchenne Muscular Dystrophy
NCT03769116A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)CompletedPhase 1/22018-12-052020-12-0841Muscular Dystrophy, Duchenne
NCT03375164A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)CompletedPhase 1/22018-01-042023-04-254Duchenne Muscular Dystrophy

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41182527Caregiver-reported Patient Experiences with Duchenne Muscular Dystrophy: Qualitative In-trial Interviews 1 Year After Delandistrogene Moxeparvovec in the Pivotal EMBARK Trial.Neurology and therapy2026cited by trial NCT05096221
PMID 41518520Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial.Neurology and therapy2026cited by trial NCT05096221
PMID 41672410ALT/CK Ratio as an Early Marker of Liver Injury After Gene Therapy in Duchenne Muscular Dystrophy.Pediatrics2026name in abstract: delandistrogene moxeparvovec
PMID 41681118Learnings from Patient Mortality after Delandistrogene Moxeparvovec Administration: A Report of Two Cases and Expert Committee Considerations for Future Mitigation and Management.Human gene therapy2026name in title: delandistrogene moxeparvovec
PMID 41854298Sirolimus for the treatment of steroid-refractory hepatotoxicity following AAV gene therapy in patients with Duchenne muscular dystrophy.Journal of neuromuscular diseases2026name in abstract: delandistrogene moxeparvovec
PMID 42237476Five-Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a Study.Muscle & nerve2026name in title: delandistrogene moxeparvovec
PMID 42944976Three-Year Follow-Up of Delandistrogene Moxeparvovec in Duchenne Muscular Dystrophy: Long-Term Phase 3 EMBARK Trial Results.Neurology and therapy2026cited by trial NCT05096221
PMID 39385046AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.Nature medicine2025cited by trial NCT05096221
PMID 39589719Caregiver Global Impression Observations from EMBARK: A Phase 3 Study Evaluating Delandistrogene Moxeparvovec in Ambulatory Patients with Duchenne Muscular Dystrophy.Neurology and therapy2025cited by trial NCT05096221
PMID 39747998Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy.Scientific reports2025cited by trial NCT04626674
PMID 40354061Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy: An Exploratory Analysis From the EMBARK Randomized Clinical Trial.JAMA neurology2025cited by trial NCT05096221
PMID 41037163Dystrophinopathies.Continuum (Minneapolis, Minn.)2025name in abstract: delandistrogene moxeparvovec
PMID 37577753Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial.Muscle & nerve2024name in title: delandistrogene moxeparvovec
PMID 38753764Validity of remote live stream video evaluation of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy.PloS one2024cited by trial NCT03375164
PMID 37539981Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR).Annals of neurology2023cited by trial NCT03375164
PMID 32539076Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial.JAMA neurology2020cited by trial NCT03375164

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41047627Real-world outcomes of delandistrogene moxeparvovec gene therapy: Motor outcomes and emerging safety concerns.Molecular therapy : the journal of the American Society of Gene Therapy2026name in title: delandistrogene moxeparvovec
PMID 41248852Drug-induced liver injury: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database (2004-2024).Annals of hepatology2026name in abstract: delandistrogene moxeparvovec
PMID 41310179Real-world experience with gene therapy in Duchenne muscular dystrophy center readiness and patients safety: report from Qatar.Gene therapy2026name in abstract: delandistrogene moxeparvovec
PMID 41422802Safety and efficacy of commercially administered elevidys (delandistrogene moxeparvovec-rokl).Molecular therapy : the journal of the American Society of Gene Therapy2026name in title: delandistrogene moxeparvovec
PMID 41919975Treatment advances for Duchenne muscular dystrophy.Current opinion in pediatrics2026name in abstract: delandistrogene moxeparvovec
PMID 41944036Incidence, Timing and Clinical Significance of Immune-Mediated Myocardial Injury and Myocarditis After Gene Replacement Therapy: A Systematic Review and Meta-Analysis.Circulation. Heart failure2026name in abstract: delandistrogene moxeparvovec
PMID 42031513Delandistrogene moxeparvovec: gene therapy for Duchenne muscular dystrophy.Archives of disease in childhood. Education and practice edition2026name in title: delandistrogene moxeparvovec
PMID 42384320Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up.Cardiology and therapy2026name in title: delandistrogene moxeparvovec
PMID 42396397Duchenne Muscular Dystrophy and Delandistrogene Moxeparvovec Gene Therapy in Children: A Systematic Review and Meta-Analysis.Neurology. Genetics2026name in title: delandistrogene moxeparvovec
PMID 42510866Recalibrating Therapeutic Priorities for Duchenne Muscular Dystrophy: A Critical Synthesis of Approved and Emerging Strategies Through the Lens of an Underrepresented Population.Genes2026name in abstract: delandistrogene moxeparvovec
PMID 42552850Safety, Tolerability, and Efficacy of a Prophylactic Sirolimus Protocol for Patients Receiving Delandistrogene Moxeparvovec-Rokl Gene Therapy.Human gene therapy2026name in title: delandistrogene moxeparvovec
PMID 42668237289th ENMC international workshop: assessing and managing emerging AAV related toxicities after gene therapy for neuromuscular disorders, 26 - 28 September 2025, Hoofddorp, The Netherlands.Neuromuscular disorders : NMD2026name in abstract: delandistrogene moxeparvovec
PMID 42841104Systemic responses to intravenous rAAV administration in boys with Duchenne muscular dystrophy.Frontiers in molecular medicine2026name in abstract: delandistrogene moxeparvovec
PMID 42998121Public Participation in U.S. Food and Drug Administration (FDA) Advisory Committees: A Qualitative Analysis.Therapeutic innovation & regulatory science2026name in abstract: delandistrogene moxeparvovec
PMID 39615430Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Requiring Intravenous Immunoglobulin.Pediatric neurology2025name in title: delandistrogene moxeparvovec
PMID 39720847Is Duchenne gene therapy a suitable treatment despite its immunogenic class effect?Expert opinion on drug safety2025name in abstract: delandistrogene moxeparvovec
PMID 39899275The latest developments in synthetic approaches to Duchenne muscular dystrophy.Expert review of neurotherapeutics2025name in abstract: delandistrogene moxeparvovec
PMID 40367405Delandistrogene Moxeparvovec Gene Therapy in Individuals With Duchenne Muscular Dystrophy: Evidence in Focus: Report of the AAN Guidelines Subcommittee.Neurology2025name in title: delandistrogene moxeparvovec
PMID 40495560Some functional improvements in placebo and Delandistrogene moxeparvovec-treated trial participants explained by increased corticosteroid dosing.Journal of neuromuscular diseases2025name in title: delandistrogene moxeparvovec
PMID 40569438Efficacy of delandistrogene moxeparvovec on Duchenne muscular dystrophy: a systematic review and meta-analysis.Human genetics2025name in title: delandistrogene moxeparvovec
PMID 40737572Delandistrogene Moxeparvovec Gene Therapy in Individuals With Duchenne Muscular Dystrophy: Evidence in Focus: Report of the AAN Guidelines Subcommittee.Neurology2025name in title: delandistrogene moxeparvovec
PMID 40763125FDA Investigating Sarepta's Elevidys® after Second Patient Dies.Human gene therapy2025name in title: Elevidys
PMID 40817386AAV microdystrophin gene replacement therapy for Duchenne muscular dystrophy: progress and prospects.Gene therapy2025name in abstract: Elevidys
PMID 40848523Gene therapy for Duchenne muscular dystrophy.Brain & development2025name in abstract: delandistrogene moxeparvovec
PMID 40868246Engineering Targeted Gene Delivery Systems for Primary Hereditary Skeletal Myopathies: Current Strategies and Future Perspectives.Biomedicines2025name in abstract: Elevidys
PMID 40985181Anaphylaxis During Delandistrogene Moxeparvovec Infusion Therapy in a Boy With Duchenne Muscular Dystrophy.Muscle & nerve2025name in title: delandistrogene moxeparvovec
PMID 41061325Reversal of Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Using Sirolimus and Immunoglobulin.Pediatric neurology2025name in title: delandistrogene moxeparvovec
PMID 41391912Gene therapy in Duchenne muscular dystrophy.Archives de pediatrie : organe officiel de la Societe francaise de pediatrie2025name in abstract: delandistrogene moxeparvovec
PMID 41403450Delandistrogene Moxeparvovec gene therapy for Duchenne muscular dystrophy: the way forward in South Asian countries.The Lancet regional health. Southeast Asia2025name in title: delandistrogene moxeparvovec
PMID 38291016Duchenne muscular dystrophy: promising early-stage clinical trials to watch.Expert opinion on investigational drugs2024name in abstract: Elevidys
PMID 38306745Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular Dystrophy.Pediatric neurology2024name in title: delandistrogene moxeparvovec
PMID 38327805Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74.Molecular therapy. Methods & clinical development2024name in abstract: delandistrogene moxeparvovec
PMID 38607761Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy.Journal of neuromuscular diseases2024name in title: delandistrogene moxeparvovec
PMID 38748280[How safe is gene therapy? : Second death after Duchenne therapy].Innere Medizin (Heidelberg, Germany)2024name in abstract: delandistrogene moxeparvovec
PMID 39098058Equitable Access of Delandistrogene Moxeparvovec for Patients With Duchenne Muscular Dystrophy: A Call for Discussion.Pediatric neurology2024name in title: delandistrogene moxeparvovec
PMID 39137177In brief: Expanded indication for Elevidys.The Medical letter on drugs and therapeutics2024name in title: Elevidys
PMID 39152743The FDA approval of delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy: a critical examination of the evidence and regulatory process.Expert opinion on biological therapy2024name in title: delandistrogene moxeparvovec
PMID 39447441Response to Hamid et al., "Equitable Access of Delandistrogene Moxeparvovec for Patients With Duchenne Muscular Dystrophy".Pediatric neurology2024name in title: delandistrogene moxeparvovec
PMID 39593150Neuromuscular diseases: genomics-driven advances.Genomics & informatics2024name in abstract: delandistrogene moxeparvovec
PMID 39607794Long-Term Survival and Myocardial Function Following Systemic Delivery of Delandistrogene Moxeparvovec in DMDMDX Rats.Human gene therapy2024name in title: delandistrogene moxeparvovec
PMID 37261034Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States.Journal of market access & health policy2023name in title: delandistrogene moxeparvovec
PMID 37497476Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy.Frontiers in cell and developmental biology2023name in title: delandistrogene moxeparvovec
PMID 37566211Delandistrogene Moxeparvovec: First Approval.Drugs2023name in title: delandistrogene moxeparvovec
PMID 37674905Paving the way for future gene therapies: A case study of scientific spillover from delandistrogene moxeparvovec.Molecular therapy. Methods & clinical development2023name in title: delandistrogene moxeparvovec
PMID 37755693Delandistrogene moxeparvovec (Elevidys) for Duchenne muscular dystrophy.The Medical letter on drugs and therapeutics2023name in title: delandistrogene moxeparvovec
PMID 38046199Development of capsid- and genome-modified optimized AAVrh74 vectors for muscle gene therapy.Molecular therapy. Methods & clinical development2023name in abstract: Elevidys

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R01AR040864Dystrophin ReplacementUNIVERSITY OF WASHINGTONCHAMBERLAIN, JEFFREY S2026–2026name in abstract: Elevidys
R01AR085068MR Assessment of the effect of nNOS on Bioenergetics and Microvascular Function in Becker and Duchenne Muscular DystrophyUNIVERSITY OF FLORIDAFORBES, SEAN C2025–2026name in abstract: Elevidys
R56NS147542Treg-mediated tolerance of dystrophin immunityUNIVERSITY OF CALIFORNIA-IRVINEVILLALTA, SERGIO ARMANDO2026–2026name in abstract: Elevidys

Notes

AAVrh74 vector with the MHCK7 promoter delivering a micro-dystrophin transgene for Duchenne muscular dystrophy. Accelerated approval 2023-06-22 for ambulatory patients aged 4-5; a 2024-06-20 supplement extended it to patients 4 and older. Development code SRP-9001.

How to cite

delandistrogene moxeparvovec (AXP000254.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000254.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.